Adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti‐CD38 monoclonal antibody. The gene discussed is CD38; the disease is AL amyloidosis.